RMS Medical Products Announces Results for Three, Ten and Twelve Months Ending December 31, 2017
- Highest Reported Twelve Month Net Sales and Net Income in RMS History
- Double-Digit Percentage Growth in Net Sales
- Increased Profitability
CHESTER, NY / ACCESSWIRE / February 13, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced the latest financial results for the three, ten and twelve months ending December 31, 2017.
The selected financial results encompass the periods since the Company's fiscal year ending on February 28, 2017. To facilitate a period-to-period comparison despite the change in the Company's fiscal year, the selected financial results also include the three and twelve-month periods ending December 31, 2017 and 2016.
Highlights Three Months Ending December 31, 2017 versus 2016
- 44% Increase in Net Sales
- 39% Increase in Gross Profit
- 14% Decrease in Operating Expenses as % of Net Sales
- 10% Increase in Net Income as % of Net Sales
|
For the Three Months Ended
December 31,
|
||||||||||||||||
|
2017
|
2016
|
$ Change
|
% Change
|
|||||||||||||
|
Net Sales
|
$ | 4,125,480 | $ | 2,871,142 | $ | 1,254,338 | 43.7 | % | ||||||||
|
Gross Profit
|
$ | 2,490,196 | $ | 1,790,629 | $ | 699,567 | 39.1 | % | ||||||||
|
Gross Profit as % of Net Sales
|
60.4 | % | 62.4 | % | -2.0 | % | ||||||||||
|
Operating Expenses
|
$ | 2,138,022 | $ | 1,878,810 | $ | 259,212 | 13.8 | % | ||||||||
|
Operating Expenses as % of Net Sales
|
51.8 | % | 65.4 | % | -13.6 | % | ||||||||||
|
Net Income
|
$ | 278,370 | $ | (90,492 | ) | $ | 368,862 | N/A | ||||||||
|
Net Income as % of Net Sales
|
6.7 | % | -3.2 | % | 9.9 | % | ||||||||||
Highlights Twelve Months Ending December 31, 2017 versus 2016
- 25% Increase in Net Sales
- 21% Increase in Gross Profit
- 12% Decrease in Operating Expenses as % of Net Sales
- 7% Increase in Net Income as % of Net Sales
|
For the Twelve Months Ended
December 31,
|
||||||||||||||||
|
2017
|
2016
|
$ Change
|
% Change
|
|||||||||||||
|
Net Sales
|
$ | 15,442,712 | $ | 12,364,285 | $ | 3,078,427 | 24.9 | % | ||||||||
|
Gross Profit
|
$ | 9,268,107 | $ | 7,680,895 | $ | 1,587,212 | 20.7 | % | ||||||||
|
Gross Profit as % of Net Sales
|
60.0 | % | 62.1 | % | -2.1 | % | ||||||||||
|
Operating expenses
|
$ | 8,127,155 | $ | 8,011,457 | $ | 115,698 | 1.4 | % | ||||||||
|
Operating expenses as % of Net Sales
|
52.6 | % | 64.8 | % | -12.2 | % | ||||||||||
|
Net Income
|
$ | 819,547 | $ | (216,123 | ) | $ | 1,035,670 | N/A | ||||||||
|
Net Income as % of Net Sales
|
5.3 | % | -1.7 | % | 7.0 | % | ||||||||||
Growth in net sales in 2017 was driven principally by increased volume with our existing customers domestically and internationally in all major product categories. The launch of a new drug generated increased needle sales and we believe the new 510(k) clearance by the FDA for the RMS "Integrated Catch-Up Freedom Syringe Drive Infusion System" on August 31, 2017, which includes specific clearance for Cuvitru® and Hizentra®, also contributed in part to increased sales. Internationally, we gained business in several new countries, a current distributor has expanded its home infusion business, and facilitated subcutaneous immunoglobulin gained traction in Europe. Also contributing to the 2017 increase was a backlog at December 31, 2016 of $0.3 million, which was filled during the current period. Excluding this backlog, net sales grew 20.2% for the twelve month period ending December 31, 2017.
The increase in gross profit was driven by the increase in net sales, which was partially offset by the increase in higher salary and related benefits costs from overtime and the addition of a second shift to meet increased demand. Furthermore, increased scrap during quality inspections also negatively impacted gross profit and the gross margin. In January 2018, we implemented a nondestructive testing protocol to reduce scrap.
Andy Sealfon, RMS Chief Executive Officer commented, "I am so pleased to announce that due to the outstanding performance and expanded market acceptance of our FREEDOM Syringe Infusion System, as well as the confirmation by the FDA of the unique technology supporting the use of our system for subcutaneous medications including Hizentra® and Cuvitru®, as well as for intravenous uses such as antibiotics, we experienced our best year ever in the Company's history for net sales and profitability. With new markets opening, planned introduction of new products this year, multiple new clinical trials underway, and international market expansions, we believe we are well positioned for future growth."
For consistency in disclosure presented in our Form 10-K for the period ending December 31, 2017 as required by SEC regulations, we are providing a presentation of the ten months ending December 31, 2017 versus twelve months ending February 28, 2017 as a result of our fiscal year end change. The variations in this presentation are due to the comparison of a ten month period versus a twelve month period. However, net sales in the ten month period were higher than the twelve month period, also due to volume increases with our existing customers domestically and internationally in all major product categories for the same reasons stated above. See Selected Financial Results attached.
About RMS Medical Products
The Company manufactures medical products used for home infusions and suctioning. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers.
The Company's website may be visited at www.rmsmedicalproducts.com.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms term "believe" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. The results of operations for the periods presented herein are not necessarily indicative of the results to be expected in the future.
For more information, please call:
Mike King
702 650 3000
Princeton Research
SELECTED FINANCIAL RESULT
|
For the Three Months Ended
December 31,
|
||||||||
|
2017
|
2016
|
|||||||
|
NET SALES
|
$ | 4,125,480 | $ | 2,871,142 | ||||
|
Cost of goods sold
|
1,635,284 | 1,080,513 | ||||||
|
Gross Profit
|
2,490,196 | 1,790,629 | ||||||
|
OPERATING EXPENSES
|
||||||||
|
Selling, general and administrative
|
2,057,616 | 1,742,701 | ||||||
|
Research and development
|
3,023 | 52,315 | ||||||
|
Depreciation and amortization
|
77,383 | 83,794 | ||||||
|
Total Operating Expenses
|
2,138,022 | 1,878,810 | ||||||
|
Net Operating Profit/(Loss)
|
352,174 | (88,181 | ) | |||||
|
Non-Operating (Income)/Expense
|
||||||||
|
Interest expense
|
— | 1,930 | ||||||
|
(Income)/loss on foreign currency exchange
|
(3,487 | ) | 46,820 | |||||
|
Other expense and interest income, net
|
(1,316 | ) | (323 | ) | ||||
|
INCOME (LOSS) BEFORE TAXES
|
356,977 | (136,608 | ) | |||||
|
Income Tax (Expense) Benefit
|
(78,607 | ) | 46,116 | |||||
|
NET INCOME (LOSS)
|
$ | 278,370 | $ | (90,492 | ) | |||
|
NET INCOME (LOSS) PER SHARE
|
||||||||
|
Basic
|
$ | 0.01 | $ | 0.00 | ||||
|
Diluted
|
$ | 0.01 | $ | 0.00 | ||||
|
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
|
||||||||
|
Basic
|
37,994,298 | 37,754,723 | ||||||
|
Diluted
|
38,649,178 | 37,802,342 | ||||||
SELECTED FINANCIAL RESULTS
|
For the Twelve Months Ended
December 31,
|
||||||||
| 2017 | 2016 | |||||||
|
NET SALES
|
$ | 15,442,712 | $ | 12,364,285 | ||||
|
Cost of goods sold
|
6,174,605 | 4,683,390 | ||||||
|
Gross Profit
|
9,268,107 | 7,680,895 | ||||||
|
OPERATING EXPENSES
|
||||||||
|
Selling, general and administrative
|
7,731,972 | 7,468,724 | ||||||
|
Research and development
|
88,621 | 246,551 | ||||||
|
Depreciation and amortization
|
306,562 | 296,182 | ||||||
|
Total Operating Expenses
|
8,127,155 | 8,011,457 | ||||||
|
Net Operating Profit/(Loss)
|
1,140,952 | (330,562 | ) | |||||
|
Non-Operating (Income)/Expense
|
||||||||
|
Interest expense
|
— | 5,298 | ||||||
|
(Income)/loss on foreign currency exchange
|
(65,651 | ) | 37,594 | |||||
|
Other expense and interest income, net
|
(3,743 | ) | (2,545 | ) | ||||
|
INCOME (LOSS) BEFORE TAXES
|
1,210,346 | (370,909 | ) | |||||
|
Income Tax (Expense) Benefit
|
(390,799 | ) | 154,786 | |||||
|
NET INCOME (LOSS)
|
$ | 819,547 | (216,123 | ) | ||||
|
NET INCOME (LOSS) PER SHARE
|
||||||||
|
Basic
|
$ | 0.02 | $ | (0.01 | ) | |||
|
Diluted
|
$ | 0.02 | $ | (0.01 | ) | |||
|
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
|
||||||||
|
Basic
|
37,873,755 | 37,877,463 | ||||||
|
Diluted
|
38,393,836 | 37,925,082 | ||||||
SELECTED FINANCIAL RESULTS
|
For the Ten
Months Ended
December 31,
2017
|
For the Twelve
Months Ended
February 28,
2017
|
|||||||
|
NET SALES
|
$ | 13,313,894 | $ | 12,293,655 | ||||
|
Cost of goods sold
|
5,174,946 | 4,724,097 | ||||||
|
Gross Profit
|
8,138,948 | 7,569,558 | ||||||
|
OPERATING EXPENSES
|
||||||||
|
Selling, general and administrative
|
6,594,570 | 7,767,712 | ||||||
|
Research and development
|
50,587 | 237,486 | ||||||
|
Depreciation and amortization
|
257,257 | 300,611 | ||||||
|
Total Operating Expenses
|
6,902,414 | 8,305,809 | ||||||
|
Net Operating Profit/(Loss)
|
1,236,534 | (736,251 | ) | |||||
|
Non-Operating (Income)/Expense
|
||||||||
|
Interest expense
|
— | 1,886 | ||||||
|
(Income)/loss on foreign currency exchange
|
(68,566 | ) | 41,499 | |||||
|
Other expense and interest income, net
|
(2,420 | ) | (2,937 | ) | ||||
|
INCOME (LOSS) BEFORE TAXES
|
1,307,520 | (776,699 | ) | |||||
|
Income Tax (Expense) Benefit
|
(402,563 | ) | 241,700 | |||||
|
NET INCOME (LOSS)
|
$ | 904,957 | $ | (534,999 | ) | |||
|
NET INCOME (LOSS) PER SHARE
|
||||||||
|
Basic
|
$ | 0.02 | $ | (0.01 | ) | |||
|
Diluted
|
$ | 0.02 | $ | (0.01 | ) | |||
|
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
|
||||||||
|
Basic
|
37,897,632 | 37,830,581 | ||||||
|
Diluted
|
38,445,482 | 37,878,201 | ||||||
SOURCE: Repro Med Systems, Inc.
Released February 13, 2018